Friedreich ataxia is a progressive neurodegenerative disorder caused by loss of function mutations in the frataxin gene. In order to unravel frataxin function we developed monoclonal antibodies raised against different regions of the protein. These antibodies detect a processed 18 kDa protein in various human and mouse tissues and cell lines that is severely reduced in Friedreich ataxia patients. By immunocytofluorescence and immunocytoelectron microscopy we show that frataxin is located in mitochondria, associated with the mitochondrial membranes and crests. Analysis of cellular localization of various truncated forms of frataxin expressed in cultured cells and evidence of removal of an N-terminal epitope during protein maturation demonstrated that the mitochondrial targetting sequence is encoded by the first 20 amino acids. Given the shared clinical features between Friedreich ataxia, vitamin E deficiency and some mitochondriopathies, our data suggest that a reduction in frataxin results in oxidative damage.
Evidence from postmortem studies suggest an involvement of oxidative stress in the degeneration of dopaminergic neurons in Parkinson disease (PD) that have recently been shown to die by apoptosis, but the relationship between oxidative stress and apoptosis has not yet been elucidated. Activation of the transcription factor NF-B is associated with oxidative stress-induced apoptosis in several nonneuronal in vitro models. To investigate whether it may play a role in PD, we looked for the translocation of NF-B from the cytoplasm to the nucleus, evidence of its activation, in melanized neurons in the mesencephalon of postmortem human brain from five patients with idiopathic PD and seven matched control subjects. In PD patients, the proportion of dopaminergic neurons with immunoreactive NF-B in their nuclei was more than 70-fold that in control subjects. A possible relationship between the nuclear localization of NF-B in mesencephalic neurons of PD patients and oxidative stress in such neurons has been shown in vitro with primary cultures of rat mesencephalon, where translocation of NF-B is preceded by a transient production of free radicals during apoptosis induced by activation of the sphingomyelindependent signaling pathway with C 2
Caspase-3 is an effector of apoptosis in experimental models of Parkinson's disease (PD). However, its potential role in the human pathology remains to be demonstrated. Using caspase-3 immunohistochemistry on the postmortem human brain, we observed a positive correlation between the degree of neuronal loss in dopaminergic (DA) cell groups affected in the mesencephalon of PD patients and the percentage of caspase-3-positive neurons in these cell groups in control subjects and a significant decrease of caspase-3-positive pigmented neurons in the substantia nigra pars compacta of PD patients compared with controls that also could be observed in an animal model of PD. This suggests that neurons expressing caspase-3 are more sensitive to the pathological process than those that do not express the protein. In addition, using an antibody raised against activated caspase-3, the percentage of active caspase-3-positive neurons among DA neurons was significantly higher in PD patients than in controls. Finally, electron microscopy analysis in the human brain and in vitro data suggest that caspase-3 activation precedes and is not a consequence of apoptotic cell death in PD.T he pathological hallmarks of Parkinson's disease (PD) are a loss of dopaminergic (DA) neurons in the mesencephalon and the presence of Lewy bodies in altered neurons. The exact cause of this neuronal loss is still unknown, but recent human postmortem studies have suggested that, in PD, nigral DA neurons die by apoptosis (1-3) as do DA neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice (4,5), an in vivo model of PD. However, the significance of purely morphological human postmortem features suggestive of apoptosis remained controversial, and the results of investigations into molecular apoptotic markers in PD brains are awaited to confirm the morphologic studies (6).Extensive in vitro studies in nonneuronal and neuronal cell systems indicate that aspartate-specific cysteine proteases (caspases) are effectors of apoptosis (7). In neurons, several lines of evidence indicate that caspase-3 (CPP32͞Yama͞Apopain), a 32-kDa cytosolic protein, plays a major role in the executive phase of apoptosis (8, 9). First, cerebral hyperplasia and cellular disorganization are observed in caspase-3-deficient mice (10). Second, neuronal death in experimental models of several acute and chronic neurodegenerative disorders has been associated with activation of caspase-3 (11-13). Third, with special reference to PD, neurotoxins commonly used to induce experimental parkinsonian syndromes, e.g., 1-methyl-4-phenylpyridinium (MPP ϩ ) and 6-hydroxydopamine (6-OHDA), have been shown to exert their proapoptotic actions via activation of caspase-3-like proteases in neuronal in vitro models (14-16). To date, however, cellular expression of caspase-3 has not been studied in postmortem brain from patients with PD or any other neurologic disorders. In the present study, we thus analyzed caspase-3 distribution and activation in PD and experimental models of the dise...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.